Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

resene paints (australia) limited - copper present as cuprous thiocyanate; copper present as cuprous thiocyanate; copper present as cuprous thiocyanate; copper present as cuprous thiocyanate; copper present as cuprous thiocyanate; zinc pyrithione; zinc pyrithione; zinc pyrithione; zinc pyrithione; zinc pyrithione - paint - copper present as cuprous thiocyanate cyanide active 226.0 g/l; copper present as cuprous thiocyanate cyanide active 228.0 g/l; copper present as cuprous thiocyanate cyanide active 247.0 g/l; copper present as cuprous thiocyanate cyanide active 247.0 g/l; copper present as cuprous thiocyanate cyanide active 251.0 g/l; zinc pyrithione mineral-zinc active 48.5 g/l; zinc pyrithione mineral-zinc active 49.5 g/l; zinc pyrithione mineral-zinc active 44.6 g/l; zinc pyrithione mineral-zinc active 48.5 g/l; zinc pyrithione mineral-zinc active 43.7 g/l - antifouling

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - liothyronine sodium (unii: gca9vv7d2n) (liothyronine - unii:06lu7c9h1v) - liothyronine sodium 5 ug - thyroid hormone drugs are indicated: - as replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. this category includes cretinism, myxedema and ordinary hypothyroidism in patients of any age (pediatric patients, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary) or tertiary (hypothalamic) hypothyroidism (see warnings ). as replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. this category includes cretinism, myxedema and ordinary hypothyroidism in patients of any age (pediatric patients, adults, the elderly), or state (including pregnancy

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - diflunisal (unii: 7c546u4den) (diflunisal - unii:7c546u4den) - diflunisal 500 mg - carefully consider the potential benefits and risks of diflunisal tablets and other treatment options before deciding to use diflunisal tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). diflunisal tablets are indicated for acute or long-term use for symptomatic treatment of the following: - mild to moderate pain - osteoarthritis - rheumatoid arthritis diflunisal tablets are contraindicated in patients with known hypersensitivity to diflunisal or the excipients (see description ). diflunisal tablets should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic/analphylactoid reactions to nsaids have been reported in such patients (see warnings , anaphylactic/anaphylactoid reactions and precautions , preexisting asthma ). diflunisal tablets are contraindicated for the treatment of peri-operative pain in the sett

United States - English - NLM (National Library of Medicine)

sentynl therapeutics, inc. - levorphanol tartrate (unii: 04wqu6t9qi) (levorphanol - unii:27618j1n2x) - levorphanol tartrate 2 mg - levorphanol tartrate tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see warnings ], reserve levorphanol tartrate tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: - have not been tolerated, or are not expected to be tolerated, - have not provided adequate analgesia, or are not expected to provide adequate analgesia levorphanol tartrate tablets are contraindicated in patients with: - significant respiratory depression [see warnings ] - acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see warnings ] - known or suspected gastrointestinal obstruction, including paralytic ileus [see warnings ] - hypersensitivity to levorphanol or any of the formulation excipients (e.g., anaphylaxis) [see wa

United States - English - NLM (National Library of Medicine)

zydus pharmaceuticals (usa) inc. - diflunisal (unii: 7c546u4den) (diflunisal - unii:7c546u4den) - carefully consider the potential benefits and risks of diflunisal tablets and other treatment options before deciding to use diflunisal tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). diflunisal tablets are indicated for acute or long-term use for symptomatic treatment of the following: 1. mild to moderate pain 2. osteoarthritis 3. rheumatoid arthritis diflunisal tablets are contraindicated in patients with known hypersensitivity to diflunisal or the excipients (see description ). diflunisal tablets should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic/analphylactoid reactions to nsaids have been reported in such patients (see warnings, anaphylactic/anaphylactoid reactions and precautions, preexisting asthma ). diflunisal tablets are contraindicated in the setting of coronary artery bypass graft (cabg) surger

United States - English - NLM (National Library of Medicine)

lannett company, inc. - levorphanol tartrate (unii: 04wqu6t9qi) (levorphanol - unii:27618j1n2x) - levorphanol tartrate tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see warnings ], reserve levorphanol tartrate tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: - have not been tolerated, or are not expected to be tolerated, - have not provided adequate analgesia, or are not expected to provide adequate analgesia levorphanol tartrate tablets are contraindicated in patients with: - significant respiratory depression [see warnings ] - acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see warnings ] - known or suspected gastrointestinal obstruction, including paralytic ileus [see warnings ]  - hypersensitivity to levorphanol or any of the formulation excipients

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - levorphanol tartrate (unii: 04wqu6t9qi) (levorphanol - unii:27618j1n2x) - levorphanol tartrate tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see warnings] , reserve levorphanol tartrate tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: levorphanol tartrate tablets are contraindicated in patients with: levorphanol tartrate tablets contains levorphanol, a schedule ii controlled substance. levorphanol tartrate tablets contains levorphanol, a substance with a high potential for abuse similar to other opioids including fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone, oxymorphone and tapentadol. levorphanol can be abused and is subject to misuse, addiction, and criminal diversion [see warnings ]. all patients treated with opioids require careful monitoring for signs of abuse and

Canada - English - Health Canada

atoms f.d. inc - benzalkonium chloride - liquid - 10% - benzalkonium chloride 10% - disinfectants (for agents used on object)

Canada - English - Health Canada

atoms f.d. inc - octyl decyl dimethyl ammonium chloride; benzalkonium chloride; dioctyl dimethyl ammonium chloride; didecyl dimethyl ammonium chloride - liquid - 1.5%; 2%; 0.6%; 0.9% - octyl decyl dimethyl ammonium chloride 1.5%; benzalkonium chloride 2%; dioctyl dimethyl ammonium chloride 0.6%; didecyl dimethyl ammonium chloride 0.9% - disinfectants (for agents used on object)

Canada - English - Health Canada

atoms f.d. inc - benzalkonium chloride - liquid - 0.3% - benzalkonium chloride 0.3% - miscellaneous local anti-infectives